Joel Greenblatt's GILD Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 299,132 shares of Gilead Sciences, Inc. (GILD) worth $36.72 M, representing 0.13% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 47 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in GILD, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2014, adding 345,239 shares. Largest reduction occurred in Q1 2019, reducing 314,073 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Gilead Sciences (GILD) Holding Value Over Time
Track share changes against reported price movement
Quarterly Gilead Sciences (GILD) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -46,765 | Reduce 13.52% | 299,132 | $122.74 |
| Q3 2025 | +63,701 | Add 22.57% | 345,897 | $111.00 |
| Q2 2025 | +31,202 | Add 12.43% | 282,196 | $110.87 |
| Q1 2025 | -5,047 | Reduce 1.97% | 250,994 | $112.05 |
| Q4 2024 | +873 | Add 0.34% | 256,041 | $92.37 |
| Q3 2024 | -26,284 | Reduce 9.34% | 255,168 | $83.84 |
| Q2 2024 | +133,164 | Add 89.80% | 281,452 | $68.61 |
| Q1 2024 | +52,866 | Add 55.40% | 148,288 | $73.25 |
| Q4 2023 | -84,227 | Reduce 46.88% | 95,422 | $81.01 |
| Q3 2023 | +68,646 | Add 61.84% | 179,649 | $74.94 |
| Q2 2023 | +11,277 | Add 11.31% | 111,003 | $77.07 |
| Q1 2023 | +20,404 | Add 25.72% | 99,726 | $82.97 |
| Q4 2022 | +345 | Add 0.44% | 79,322 | $85.85 |
| Q3 2022 | -13,887 | Reduce 14.95% | 78,977 | $61.69 |
| Q2 2022 | -10,651 | Reduce 10.29% | 92,864 | $61.81 |
| Q1 2022 | +18,160 | Add 21.28% | 103,515 | $59.45 |
| Q4 2021 | -31,662 | Reduce 27.06% | 85,355 | $72.61 |
| Q3 2021 | +24,187 | Add 26.06% | 117,017 | $69.85 |
| Q2 2021 | -9,504 | Reduce 9.29% | 92,830 | $68.86 |
| Q1 2021 | -45,359 | Reduce 30.71% | 102,334 | $64.63 |
| Q4 2020 | +81,414 | Add 122.84% | 147,693 | $58.26 |
| Q3 2020 | -25,000 | Reduce 27.39% | 66,279 | $63.19 |
| Q2 2020 | -65,368 | Reduce 41.73% | 91,279 | $76.94 |
| Q1 2020 | -94,403 | Reduce 37.60% | 156,647 | $74.76 |
| Q4 2019 | -211,763 | Reduce 45.76% | 251,050 | $64.98 |
| Q3 2019 | +178,621 | Add 62.85% | 462,813 | $63.38 |
| Q2 2019 | +44,776 | Add 18.70% | 284,192 | $67.56 |
| Q1 2019 | -314,073 | Reduce 56.74% | 239,416 | $65.01 |
| Q4 2018 | +193,250 | Add 53.64% | 553,489 | $62.55 |
| Q3 2018 | -56,012 | Reduce 13.46% | 360,239 | $77.21 |
| Q2 2018 | -121,051 | Reduce 22.53% | 416,251 | $70.84 |
| Q1 2018 | -127,490 | Reduce 19.18% | 537,302 | $75.39 |
| Q4 2017 | -31,830 | Reduce 4.57% | 664,792 | $71.64 |
| Q3 2017 | -267,099 | Reduce 27.72% | 696,622 | $81.02 |
| Q2 2017 | -248,315 | Reduce 20.49% | 963,721 | $70.78 |
| Q1 2017 | +186,833 | Add 18.22% | 1.21 M | $67.92 |
| Q4 2016 | +101,669 | Add 11.01% | 1.03 M | $71.61 |
| Q3 2016 | -92,608 | Reduce 9.11% | 923,534 | $79.12 |
| Q2 2016 | +48,500 | Add 5.01% | 1.02 M | $83.42 |
| Q1 2016 | +93,396 | Add 10.68% | 967,642 | $91.86 |
| Q4 2015 | -62,736 | Reduce 6.70% | 874,246 | $101.19 |
| Q3 2015 | -131,146 | Reduce 12.28% | 936,982 | $98.19 |
| Q2 2015 | -39,604 | Reduce 3.58% | 1.07 M | $117.08 |
| Q1 2015 | +98,270 | Add 9.73% | 1.11 M | $98.13 |
| Q4 2014 | +345,239 | Add 51.98% | 1.01 M | $94.26 |
| Q3 2014 | +197,370 | Add 42.28% | 664,223 | $106.45 |
| Q2 2014 | +466,853 | New Buy | 466,853 | $82.91 |
Joel Greenblatt's Gilead Sciences Investment FAQs
Joel Greenblatt first purchased Gilead Sciences, Inc. (GILD) in Q2 2014, acquiring 466,853 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Gilead Sciences, Inc. (GILD) for 47 quarters since Q2 2014.
Joel Greenblatt's largest addition to Gilead Sciences, Inc. (GILD) was in Q2 2014, adding 466,853 shares worth $38.71 M.
According to the latest 13F filing for Q4 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 299,132 shares of Gilead Sciences, Inc. (GILD), valued at approximately $36.72 M.
As of the Q4 2025 filing, Gilead Sciences, Inc. (GILD) represents approximately 0.13% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Gilead Sciences, Inc. (GILD) was 1,212,036 shares, as reported at the end of Q1 2017.